Investing.com - Financial Markets Worldwide

Jefferies raises Celcuity stock price target to $79 on positive trial data

Published 15/08/2025, 10:56
Jefferies raises Celcuity stock price target to $79 on positive trial data
CELC
4.05%

Investing.com - Jefferies raised its price target on Celcuity Inc (NASDAQ:CELC) to $79.00 from $54.00 on Friday, while maintaining a Buy rating on the stock. The company, currently valued at $2.11 billion, is trading near its 52-week high of $53.40.

The price target increase follows what Jefferies described as "unprecedented" progression-free survival data from a Phase III study in second-line PIK3CA wild-type HR+/HER2- advanced breast cancer.

Jefferies noted that while Celcuity stock has already surged substantially, gaining 277% following the data release, the firm believes additional upside potential remains.

The research firm highlighted upcoming catalysts, including data from the PIK3CA-mutant Phase III study expected in the fourth quarter of 2025 and potential approval in the wild-type indication likely in 2026, following an NDA filing planned for the fourth quarter of 2025.

Celcuity also plans to present results from the wild-type Phase III trial at an upcoming medical meeting, which Jefferies suggests could further de-risk the company’s outlook.

In other recent news, Celcuity reported a second-quarter loss of $1.04 per share, which did not meet analysts’ expectations of a $0.88 loss. This resulted in an 18.18% negative surprise for investors. Despite the earnings miss, the company announced positive trial data and extended patent exclusivity. These developments are crucial as they could impact Celcuity’s future performance and strategic positioning. The company’s recent financial performance highlights the challenges it faces in aligning with market expectations. Investors may find the extended patent exclusivity a positive sign, potentially offering Celcuity a competitive advantage. However, the earnings miss remains a significant point of concern.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.